NexImmune, Inc.

NexImmune, Inc.'s next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2024, NexImmune, Inc. has 1.39M shares outstanding.

As of June 30, 2024, NexImmune, Inc. maintains a current ratio of 0.66, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2024, NexImmune, Inc. posted a negative return on equity (ROE) of -230.06, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -140.56, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 17.00, a quick read on workforce productivity versus industry peers.

As of the close on September 8, 2026, NexImmune, Inc.'s stock has gained approximately 9900.00% over the past 52 weeks. The 50-day moving average sits at 0.04, while the 200-day moving average is 0.27.

Over the twelve months ended June 30, 2024, NexImmune, Inc. generated - - in revenue and converted that into -20.62M in net income, yielding earnings per share of -17.38. EBITDA reached -20.95M, while operating income came in at -20.16M.

These figures are as of June 30, 2024. Total book value stands at 920,539.00, with working capital of -1.61M providing operational flexibility.

NexImmune, Inc. produced -17.61M in operating cash flow over the twelve months ended June 30, 2024. After subtracting -981.00 in capital expenditures, free cash flow totaled -17.61M - equivalent to -14.84 per share.

NexImmune, Inc.'s most recent stock split took place on October 19, 2023 with a 25:1 split ratio.